Biopharma markets are never dull. The winners win big and the companies that lose are harshly penalized. Now the dust has settled, here's the final tally from Evaluate Pharma's review of biopharma markets in 2016.
A dermatitis drug on track for annual sales of $4.6 billion in 2022? Evaluate Pharma has released its projections for the top 10 drug approvals of 2017, with a mixture of already-famous names and some surprise entries.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Drug patents are always more complicated than they seem, but a new infographic from Dickson Data spells out some of what you need to know in 2017, in an easily consumable way.
The unpredictable president-elect has made industry forecasting a much tougher job. But the show must go on. Here are some highlights from Evaluate Pharma's new 2017 biopharma report; the winners, the losers and more.